[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fbpqz30p5phle":3},{"data":4,"error":8},{"id":5,"documentId":6,"heading":7,"body":8,"slug":9,"name":9,"name_ar":8,"proprietary_name":8,"non_proprietary_name":8,"is_proprietary":8,"active_ingredient":8,"administration_route":8,"available_strength":8,"dosage_form":8,"dose_schedule":8,"drug_unit":8,"is_available_generically":8,"mechanism_of_action":8,"overdosage":8,"warning":8,"species":10,"citations":11,"dose_schedules":33,"available_strengths":46,"label_statements":55,"drug_classes":67,"specialties":80,"medical_conditions":81,"animal_species":82},2246,"ooi8bpv5fscbugs521bexq4y","تريبتورلين",null,"triptorelin",[],[12,18,22,26],{"source":13,"licence":14,"source_url":15,"harvested_by":16,"retrieved_at":17},"EMA centrally authorised medicines","EMA reuse with attribution","https:\u002F\u002Fwww.ema.europa.eu\u002Fen\u002Fdocuments\u002Freport\u002Fmedicines-output-medicines-report_en.xlsx","load-reference-corpus.cjs","2026-09-07",{"source":19,"licence":20,"source_url":21,"harvested_by":16,"retrieved_at":17},"FDA Green Book","US public domain","https:\u002F\u002Fanimaldrugsatfda.fda.gov\u002Fadafda\u002Fapp\u002Fsearch\u002Fpublic\u002FingredientsInformationExcel\u002FSection2ActiveIngredients",{"source":23,"licence":24,"source_url":25,"harvested_by":16,"retrieved_at":17},"UK VMD PID","OGL v3.0","https:\u002F\u002Fwww.vmd.defra.gov.uk\u002Fproductinformationdatabase\u002Fdownloads\u002Fvmd_productinformationdatabase.xlsx",{"claims":27,"source":28,"licence":29,"source_url":30,"harvested_by":31,"retrieved_at":32},"Arabic name (heading)","bAItari term layer and label review (model-written, reviewer-confirmed)","original Arabic name","https:\u002F\u002Fbaitari.vet\u002Fdrugs\u002Ftriptorelin","apply-label-arabic.cjs label-core-2026-10-23","2026-10-23",[34,41],{"id":35,"dose_text":36,"species":37,"administration_route":38,"limitation":39,"source_label":40},18099,"Administer 200 mcg intravaginally approximately 96 hours after weaning.","Swine (Sows)","Intravaginal","Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals. Should not be used in sows with obvious reproductive tract abnormalities.","OvuGel™",{"id":42,"dose_text":43,"species":8,"administration_route":44,"limitation":8,"source_label":45},18100,"OvuGel® should be administered intravaginally at approximately 96 hours after weaning. The product should be warmed at room temperature for a minimum of 10 minutes prior to use. Insert the delivery tube into the vagina so that the tip rests 1\u002F2 inch (1-3 cm) posterior to the cervix. Use a separate sheath over the delivery tube for each sow treated. Each sow should receive a single 2 mL dose of OvuGel®. Sows should be inseminated 22 +\u002F- 2 hours following administration of OvuGel® using standard artificial insemination techniques. Sows should be exposed to a boar during time of insemination. (See end of package insert for more detailed directions for OvuGel® administration).","VAGINAL","OvuGel®",[47,51],{"id":48,"strength_text":49,"dosage_form":50,"proprietary_name":40,"species":37,"source_label":40},15721,"Each milliliter of gel contains 100 micrograms (mcg) triptorelin as triptorelin acetate.","Gel",{"id":52,"strength_text":53,"dosage_form":8,"proprietary_name":8,"species":8,"source_label":54},15722,"100 ug \u002F 1 mL","OvuGel",[56,60,63],{"id":57,"kind":58,"statement":59,"species":37,"limitation":39,"source_label":40},26924,"indication","For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination.",{"id":61,"kind":58,"statement":62,"species":8,"limitation":8,"source_label":54},26925,"For the synchronization of time of insemination in weaned sows to facilitate a single fixed-time artificial insemination. Not approved for use in gilts. Safety and effectiveness have not been evaluated in these animals.",{"id":64,"kind":65,"statement":66,"species":8,"limitation":8,"source_label":45},26926,"warning","WITHDRAWAL PERIOD:\nNo withdrawal period is required when used according to labeling.\nUSER SAFETY WARNINGS:\nNot for Use in Humans. Keep Out of Reach of Children. The Material Safety Data Sheet (MSDS) contains more detailed occupational safety information.\nANIMAL SAFETY WARNINGS:\nOvuGel® should not be used in sows with obvious reproductive tract abnormalities.",[68,74],{"id":69,"documentId":70,"slug":71,"name":72,"heading":73},1186,"xm4lzmdojae2m2rcy1ovfh1m","hypothalamic-hormone-receptor-agonists","Hypothalamic Hormone Receptor Agonists","ناهضات مستقبِل الهرمون الوطائي",{"id":75,"documentId":76,"slug":77,"name":78,"heading":79},1181,"cdpduomk9igzpkw46fvfegg7","gonadotropin-releasing-hormone-receptor-agonists","Gonadotropin Releasing Hormone Receptor Agonists","ناهضات مستقبِل هرمون محرِّر الغونادوتروبين",[],[],[]]